Orthofix Medical (OFIX) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Orthofix Medical

NasdaqGS•Healthcare•Medical Devices

$9.15-0.14(-0.02%)Pre-market

Market Cap

$365.29M

P/S

0.4x

P/B

0.9x

Orthofix Medical Inc., together with its subsidiaries, operates as a medical technology company in the United States, Italy, the United Kingdom, France, Germany, Brazil, and internationally. It operates through two segments, Global Spine and Global Limb Reconstruction. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulation devices that enhance bone fusion; designs, develops, and markets a portfolio of spine fixation implant products for use throughout the spinal column; and offers bone graft substitutes, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers in various forms with supporting graft delivery solutions to treat various spinal, orthopedic, and dental conditions. This segment also designs, develops, and markets a portfolio of navigation technologies, including tracked surgical tools, intelligent software, and imaging equipment based on machine-vision and optical innovations; and 7D FLASH Navigation System, a navigation platform for spinal and cranial procedures. The Global Limb Reconstruction segment offers products and solutions for the underserved limb reconstruction market, including deformity correction, limb lengthening, complex fracture management, and limb preservation. This segment also designs, develops, and markets external and internal fixation limb reconstruction products that are coupled with enabling digital technologies to support the entire patient care continuum. It sells its products through distributors and sales representatives to hospitals, healthcare organizations, healthcare providers, ambulatory surgery centers, and out-patient hospitals. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in July 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.

How this company scores

AverageMetricSide Score: 47/100

Strongest: Profitability (17/25); weakest: Cash & Earnings Quality (5/25).

Profitability17/25

Growth14/25

Balance Sheet & Red Flags11/25

Cash & Earnings Quality5/25

Strengths

Long cash runwayProfit converts from growthConsistent growthImproving margins

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 0.4x5y range 0.0x – 1.6x

Currently below its 20-quarter median.

P/B · 0.9x5y range 0.0x – 2.1x

Currently near its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

FCF consistently trails net income (avg -0.7x) — earnings may be inflated by non-cash items or aggressive accounting.

Price & Volume

Market Cap $365.29M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $833.19M
Q. Revenue: $210.93M
TTM EBITDA: $13.66M
TTM Op. Income: $-39.12M
Q. Op. Income: $-8.13M
TTM Net Income: $-61.72M
Q. Net Income: $-15.80M
EPS: $-0.39
Shares Out.: $40.91M

$833.19M in TTM revenue grew 3.0% YoY, reaching $210.93M last quarter. TTM EBITDA of $13.66M and TTM operating income of $-39.12M show growth is flowing through to the bottom line. However, net income is negative at $61.72M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 71.0%
EBITDA Margin: 2.4%
Op. Margin: -3.9%
Net Margin: -7.5%

Op. margin of -3.9% is up 4.0% YoY — cost efficiency is improving. Net margin at -7.5% and gross margin of 71.0% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 51% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 0.4x
P/B Ratio: 0.9x

P/S of 0.4x and P/B of 0.9x. P/S is low relative to typical market levels.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $873.02M
Cash: $103.81M
Long-Term Debt: $221.59M
Book Value: $429.18M
D/E Ratio: 0.5
Debt/EBITDA: 43.1

With $873.02M in assets and $221.59M in long-term debt, D/E is 0.5and book value is $429.18M — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has risen for 2 consecutive quarters — a weakening trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-6.22M
TTM Free Cash Flow: $-27.82M
FCF Margin: -3.3%
FCF / Net Income: 0.5

TTM FCF of $-27.82M on $-6.22M in operating cash flow. The FCF / Net Income ratio of 0.5x means cash covers only part of net income — earnings quality needs attention. Across the last 8 quarters, free cash flow has fallen for 2 consecutive quarters — a weakening trend.